Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In a single-arm, multicenter, Phase 2 trial, bevacizumab in combination with docetaxel and carboplatin achieved a pathological complete response in 19 of 45 patients with stage II/III triple-negative breast cancer. Forty-four of the 45 patients completed the planned six cycles and toxicity was manageable. One patient had delayed wound healing as a subsequent surgical complication. Thus, bevacizumab may provide significant improvement in neoadjuvant strategies for triple-negative breast cancer and further investigation is warranted.

Bevacizumab-Docetaxel-Carboplatin Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer